ArticleJournal of clinical microbiology2014
Impact of new antifungal breakpoints on antifungal resistance in Candida species.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Antifungal Susceptibility and Multilocus Sequence Typing of Pichia kudriavzevii (Candida krusei) from a Tertiary Hospital in Shanghai.Mycopathologia · 2026Article
- Impact of Biofilm Formation by VaginalJournal of fungi (Basel, Switzerland) · 2025Article
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.World journal of virology · 2024Article
- A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistantHeliyon · 2024Article
- Nanotechnology-based Drug Delivery of Topical Antifungal Agents.Pharmaceutical nanotechnology · 2024Review
- Nanotechnology-Based Approaches for Voriconazole Delivery Applied to Invasive Fungal Infections.Pharmaceutics · 2023Review
- Antifungal Drug Concentration Impacts the Spectrum of Adaptive Mutations in Candida albicans.Molecular biology and evolution · 2023Article
- Article
- Species Distribution and Antifungal Susceptibility Pattern of Candida Recovered from Intensive Care Unit Patients, Vietnam National Hospital of Burn (2017-2019).Mycopathologia · 2021Article
- Emerging of Fatal Colitis with Multidrug-ResistantCase reports in transplantation · 2021Article
- Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species.Scientific reports · 2020Article
- Do we need to adopt antifungal stewardship programmes?European journal of hospital pharmacy : science and practice · 2020Article
- Evaluation of the Antifungal Activity ofMolecules (Basel, Switzerland) · 2019Article
- European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute breakpoints-the only point that matters in candidemia?Journal of thoracic disease · 2019Article
- Determination of antimicotic susceptibility pattern ofJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Genotyping ofCurrent medical mycology · 2018Article
- Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.The Pediatric infectious disease journal · 2018Article
- Investigating cross-contamination by yeast strains from dental solid waste to waste-handling workers by DNA sequencing.MicrobiologyOpen · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.